Objective: To investigate the association between abacavir (ABC) use and recurrent myocardial infarction (MI) among HIV-positive people with a prior MI.
Design: International multicohort collaboration with follow-up from 1999 to 2016.
Methods:
The rate of recurrent MI was described among D:A:D participants who experienced an index MI whilst in the study, and who remained under follow-up beyond 28 days after this MI. Follow-up was considered to the date of next MI, death, 1 February 2016 or 6 months after last clinic visit. Poisson regression models considered associations between recurrent MI and exposure to ABC (use at index MI, current post-MI exposure and cumulative exposure), before and after adjusting for calendar year.
Results: The 984 individuals who experienced an index MI during the study (91.3% male, median age 51 at index MI) were followed for 5312 person-years, over which time there were 136 recurrent MIs (rate 2.56/100 person-years, 95% confidence interval 2. 13-2.99 
Methods

Study design
The D:A:D study was an observational study of more than 49 000 HIV-1-positive patients from 11 cohorts from Europe, Australia, and the United States [7] . The primary study aim was to investigate associations between the use of ART, and the risk of cardiovascular disease (CVD) and other major disease events. The standardized dataset, collected prospectively during routine clinic visits, includes information on sociodemographic factors, AIDS events and deaths, risk factors for CVD, laboratory markers for monitoring HIV (including CD4 þ cell count and HIV RNA) and CVD, ART and treatments that influence CVD risk.
Information on incident MI events was reported to the study co-ordinating centre via a study event form which captured detailed information about the event and related circumstances. Each reported event was validated and coded using criteria applied in the WHO Multinational mONItoring of trends and determinants in CArdiovascular (MONICA) disease study [8] , with this process being performed blind to information about the patient's ART status. Reported MIs were classified as definite, possible or unclassifiable using standardized criteria for classification including relevant symptoms, relevant increase and decline in cardiac enzymes, ischemic changes in electrocardiographic readings and, in cases of death, autopsy results if available. Fatal MI events were additionally validated using information collected on the Coding of Causes of Death (CoDe) form [9] , and all complex and/or fatal MI cases were additionally validated with the input of an independent cardiologist.
Statistical methods
We considered the rate of recurrent MI among D:A:D participants who experienced an MI during study followup (the 'index' MI) and who remained alive and under follow-up at 28 days post-MI (to exclude any index MIs resulting in death). Follow-up was considered from 28 days post-MI to the first date of next MI, death, 1 February 2016 or 6 months after last clinic visit. Sixtyfour of the individuals (6.5%) had experienced an MI prior to D:A:D entry (and prior to the index MI); to be consistent with the main D:A:D analyses, we did not exclude this subgroup, but sensitivity analyses (which excluded the subgroup) suggested that our findings were robust to their inclusion.
Poisson regression models were used to evaluate associations between recurrent MI and exposure to ABC. As in previous analyses of the dataset [5] , each individual's follow-up was split into a series of consecutive 1-month periods, and his/her clinical, immunologic and virologic status at the start of each period was established. Three different exposures to ABC were considered: use of ABC at the time of initial MI (time-fixed); current, post-MI exposure (time-updated, defined as currently receiving ABC or having received the drug at any time in the 6 months leading up to the start of each month) and cumulative exposure (time-updated, including exposure both pre and post-MI and scaled to reflect a 5-year increment). Fixed confounders considered were sex, ethnic group, and mode of HIV acquisition. Timeupdated covariates considered were calendar year, age
Results
Of the 1191 participants who developed an index MI during the study, 984 remained under follow-up for at least 28 days and were included in the study. These individuals were largely male (91.3%) and infected with HIV through sex between men (58.8%). At the time of the index MI, the participants had a median age of 51 years [inter-quartile range (IQR) 45-59], the majority were current (55.5%) or ex-smokers (24.3%), 14.3% had a family history of MI, and most had either a moderate (10-20%, 33 .0%) or high (>20%, 27.1%) 10-year predicted Framingham risk for CVD. The index MI had occurred in 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010, 2011 In all, 503 (51.2%) people had received ABC prior to their index MI for a median of 3.1 years (range 0-13.9) of whom 327 were still on ABC at the time of the index MI. Two hundred and thirty-nine of the 327 (73.1%) stopped the drug at a median of 323 (range 0-5252) days after MI, with 71 of them subsequently re-starting the drug. Eighty of the 481 participants who had not previously received ABC prior to the index MI (16.6%) started the drug for the first time at a median of 1089 (range (Table 1) . Whilst earlier calendar year, a non-sexual or injection drug use route of HIV acquisition and a prior diagnosis of diabetes were each associated with an increased risk of recurrent MI in univariate analyses (Table 1) , adjustment for these factors did not reveal any significant associations with exposure to ABC.
Conclusion
Whilst previous study findings have suggested that current use of ABC in HIV-positive people is associated with an almost doubling in MI risk [1], we found no evidence that use of ABC was associated with an elevated risk of recurrent MI in those with a previous MI. Although most of the continued/new ABC use in those with an MI was in the earlier years of the study, when the risk of recurrent MI was higher than it is currently [10] [11] [12] , adjustment for calendar year did not modify our findings.
Whilst these results appear to contradict with previous findings, there are two main reasons why we might expect the association with ABC exposure to differ in those with a prior MI. Firstly, recurrent MIs in those with an index MI are more likely to reflect the uptake and success of post-MI interventions to manage CVD and prevent subsequent cardiovascular events in this group than differences in established risk factors for a primary MI. Our finding that few of the established CVD risk factors are associated with recurrent MI, other than diabetes, supports the existence of a different set of risk factors for recurrent MI, a notion which is consistent with the limited literature from the general population [13] [14] [15] . Secondly, one of the reasons for the continued debate about the potential association between ABC and MI is that there is no confirmed biological mechanism for the association. Arguably, the most promising potential mechanism to date relates to the association reported between ABC and platelet reactivity [16] [17] [18] , a mechanism that would be consistent with the apparent reversible nature of the ABC association with MI; a similar association has also recently been described with protease inhibitors [19] . We would, however, expect the majority of those with an MI to be receiving antiplatelet therapy, more recently with the dual combination of aspirin and clopidogrel, which could plausibly modify any effects of ABC on platelet reactivity. Unfortunately, we do not collect detailed information on the clinical presentation of each MI or on subsequent management and are therefore unable to assess the numbers treated in this way to test this hypothesis.
We note that our aim in the present study was to exclude the possibility that any of the established CVD risk factors may have confounded (and possibly obscured) an association with ABC rather than to identify risk factors for recurrent MI per se. For this reason, we have not investigated these established risk factors in more depth, or the potential role of chronic kidney disease, a factor previously demonstrated to be associated with CVD risk in the study [20] ; information on the latter was often unavailable in the earlier years of the study, although, in more recent years, ABC may have been a treatment of choice in people with chronic kidney disease. Furthermore, we do not capture information on lifestyle/ behavioural modifications, and so cannot investigate whether any changes in these may have modified the subsequent risk of recurrent MI and/or its association with continued or new ABC use. We cannot, therefore, rule out the possibility that our findings may result from residual confounding due to different post-MI management among those who are and are not receiving ABC.
In summary, among people with a previous MI, there was no evidence for an association between use of ABC post-MI and an elevated risk of a recurrent MI.
